Please assess the completion status of the following clinical trial:

Trial Title: A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with peripheral arterial disease~* Participants must be 18 to 85 years of age~* Females must be postmenopausal or sterile~Exclusion Criteria:~* Participans with hepatic, HIV, endocrine, connective tissue, psychiatric disorders or uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- MK-0736 (Type: EXPERIMENTAL): Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be orally administered placebo once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).